Shots: The US FDA has accepted the NDA and granted PR for TAK-721 for the treatment of EoE. If approved, TAK-721 will be the first FDA-approved treatment for EoE and Takeda plans to launch it under the trade name Eohilia The NDA filing is based on P-III ORBIT-1 and ORBIT-2 studies which evaluated the safety […]Read More
